Ligand Pharmaceuticals – Glucagon CVR (LGNXZ)
OTC PINK OTC PINK Primary Summary
Ligand Pharmaceuticals – Glucagon CVR (LGNXZ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ligand Pharmaceuticals – Glucagon CVR ever had a stock split?
Ligand Pharmaceuticals – Glucagon CVR Profile
| Pharmaceuticals Industry | Healthcare Sector | Todd C. Davis CEO | OTC PINK Exchange | 53220K181 CUSIP |
| US Country | 47 Employees | 15 Mar 2022 Last Dividend | - Last Split | 18 Nov 1992 IPO Date |
Overview
Ligand Pharmaceuticals Incorporated is an innovative biopharmaceutical company dedicated to the development and licensing of biopharmaceutical assets across the globe. Since its establishment in 1987, the company has been at the forefront of creating breakthrough solutions in the healthcare sector. Having its base in Jupiter, Florida, Ligand Pharmaceuticals has fostered alliances, licenses, and other business relationships with leading industry players including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Additionally, the company is a provider of Captisol materials, enhancing the delivery and performance of pharmaceuticals.
Products and Services
Ligand Pharmaceuticals Incorporated has developed a portfolio of commercial programs and products targeting a wide range of medical conditions:
- Kyprolis & Evomela: These are treatments for multiple myeloma.
- Rylaze: A recombinant erwinia asparaginase intended for managing acute lymphoblastic leukemia or lymphoblastic lymphoma in both adult and pediatric patients.
- Filspari: Under development for rare kidney diseases, this is a dual endothelin and angiotensin II receptor antagonist. It is being investigated as a non-immunosuppressive treatment for immunoglobulin A nephropathy.
- Teriparatide injection: This product is used for treating osteoporosis.
- Vaxneuvance & Pneumosil: These are aimed at preventing invasive diseases caused by Streptococcus pneumoniae serotypes, with Pneumosil targeting pneumococcal pneumonia among children.
- TZIELD: A CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D.
- Nexterone: A captisol-enabled formulation of amiodarone.
- Zulresso: A captisol-enabled formulation of brexanolone for the treatment of postpartum depression.
- Veklury: An antiviral treatment for moderate or severe COVID-19.
- Noxafil-IV: A captisol-enabled formulation of posaconazole for IV use.
- Duavee: Designed for the treatment of post-menopausal symptoms in women.
- Exemptia: For autoimmune diseases.
- Vivitra: Aimed at treating breast cancer.
- Bryxta & Zybev: Developed for various indications.
